-
ProductsRealizing the Concept of "Practitioner of Precision Medicine"
-
SolutionOne-stop Space Biology Solution for Multi-application Scenarios
-
Technical ServicesPerfect multi-omics (DNA\RNA \protein) detection platform
-
About UsBeijing Fino Weikang Biotechnology Co., Ltd.
-
Consulting Dynamics
01
2023
-
12
Meeting Invitation | Finowicom Invites You to Join P4 2023 for the 7th Cancer Precision Medicine Conference
P4 2023's 7th International Conference on Precision Oncology Medicine will be set sail again in Beijing from December 7 to 8, with more than 60 academicians/regulators/clinicians/scientific research authoritative experts and KOL, a precision drug company/diagnostic company, leading the attendance, and more than 1000 industry elite representatives in the field of precision medicine gathered at the scene. The conference will discuss the industry's pain points and annual hot topics in depth, and explore the latest regulations on tumor precision medicine, early screening/diagnostic technology innovation and commercialization path, immunotherapy/targeted drug precision development, clinical precision medicine/diagnosis and treatment path with industry experts!
P4 2023 7th International Conference on Precision OncologyWill be7-8 DecemberInBeijingregaining momentum and setting sail,More than 60 academicians/Supervision/Clinician/Scientific Research Authority and Precision Pharmaceutical Company/Diagnostic Company KOLLeading the attendance,More than 1000Industry elite representatives in the field of precision medicineGather at the scene. The conference will discuss the industry's pain points and annual hot topics in depth, and explore the latest regulations on tumor precision medicine, early screening/diagnostic technology innovation and commercialization path, immunotherapy/targeted drug precision development, clinical precision medicine/diagnosis and treatment path with industry experts!
FinowicamInvited to participate in this industry event, will bring the company's core products and services to the conference (Booth: B08), I hope to have in-depth communication and study with teachers and industry colleagues offline.
Locations of Finowicam Booth
Early screening and early diagnosis venue:Single Cancer/Multiple Cancer/Pan-cancer early screeningLatest progress/Business model,differential diagnosis of benign and malignantTechnological innovation/product landing
CMDE Related Experts
DINK PEAKVice President of the Second Affiliated Hospital of Zhejiang University School of Medicine
Open to Sponsors
"Consumer Medical Care" Model: A Feasible Commercial Exploration of Early Tumor Screening
gao yu,Nuohui Health CFO
Roundtable Discussion: Where is the road ahead for the promotion and commercialization of the tumor early screening industry?
-
IVD Registration Declaration Standardization and Challenges
-
LDT progress and standardized guidance
-
Business model selection considerations: ToH, ToB (physical examination center), ToG, ToC, etc.
-
Sailor
Experts of National Center for Temporary Examination
hu yunfu,PanshengziChief Medical Officer
wang zhaohui,Vice President of Aikang Group
Ding Wen, Ping An Health Insurance Chief Actuary.
cai daqing,Founding Managing Partner, Sherpa Equity Investment Management Limited
The first MSI companion diagnosis approved case sharing in China
zheng limou,Ed CreaturesFounder, Chairman
Based onMERCURYAdvances in multi-omics liquid biopsy technique for early screening of pan-cancer species
shaoyang,World and geneFounder and CEO
Multi-omics liquid biopsy for early non-invasive screening of pan-cancer species
Chang Silver,Product Director, Siqin Medical
PCR/sequencing and other instruments and related solutions to help accurate tumor detection
Open to Sponsors
Research progress and benefit scenarios of early detection of multiple cancer species
cai shangli,Vice President, Burning Stone Medicine, Medicine and Data Science
Blue Sea Exploration of Early Screening for Pancreatic Cancer: Latest Progress in Clinical Application of Serum microRNA
zhang chenyu,Dean, School of Life Sciences, Nanjing University
The latest clinical mid-term results of ctDNA ctRNA combined detection and early screening of lung cancer
chen minhan,CEO and Medical Director of Lusheng Bio
Breakthrough Early Screening and Early Diagnosis of Gastric Cancer Based on Blood miRNA
Zou Ruiyang,Co-founder, CEO and Chief Technology Officer of Mi Rui (Hangzhou) Biotechnology Co., Ltd.
Clinical research/scientific research transformation venue:ApplicationSingle Cell/Spatio-temporalequal multi-omics technique/Organoids/AIand other cutting-edge methods,Discovery of new markers for diagnosis and treatment/oncology clinical research and research transformation
Shin Zhanlong,Chief Physician, Department of Gastrointestinal Surgery, Peking University People's Hospital
Bai Fan,Researcher, Center for Biomedical Frontier Innovation, Peking University
Ikefa
Accurate Application and Clinical Transformation of DNA Methylation in Early Screening and Early Diagnosis of Gynecological Tumors
wang yudong,Vice President and Chief Gynecologist of International Peace Maternal and Child Health Hospital of China Welfare Association
From Disease Mechanism to Diagnosis and Treatment Target-Biomarker Driven Precision Medicine Transformation
huang chao-lan,Deputy Director, Medical Science Research Center, Peking Union Medical College Hospital
Evaluation criteria for the application of third-generation sequencing technology in tumor screening/diagnosis
Experts of In Vitro Diagnostic Reagent Inspection Institute of China Inspection Institute
The latest research on the application of tumor organoid transformation and the mechanism of tumor occurrence and tumor microenvironment
huang lai-qiang,Professor of Tsinghua University, China, Leader of Life Sciences and Biomedicine at Tsinghua University Shenzhen Graduate School
Mechanism of single cell sequencing and organoid technology in the application of hepatobiliary tumor heterogeneity and drug resistance
Gao Dong,Researcher, Research Leader, Doctoral Supervisor, Molecular Cell Center of Excellence, Chinese Academy of Sciences
AI/third generation/single cell sequencing/omics and other scientific research/clinical research solutions
Tongze Hexin
Spatial phenotype analysis combined with AI and other new pathological methods and clinical application of tumor transformation
zhang bo,Department of Pathology, Peking University Health Science Center/Department of Pathology, Third Hospital, Professor/Chief Physician, Doctoral Supervisor
Novel nasopharyngeal carcinoma marker P85-Ab: discovery and transformation
ge shengxiang,Deputy Director, Department of Laboratory, School of Public Health, Xiamen University, Head of Diagnostic Reagents, National Engineering Research Center for Infectious Disease Diagnostic Reagents and Vaccines
Single-cell sequencing of urothelial carcinoma reveals the role of macrophages and CD8 T cells in disease progression and response to immunotherapy
li xuesong,Deputy Director, Chief Physician, Professor, Department of Urology, Peking University First Hospital, Dean of Miyun Hospital, Peking University First Hospital
Application of nuclear medicine in clinical diagnosis/treatment of tumors: new progress in the integration of nuclear medicine diagnosis and treatment
zhu zhaohui,Executive Deputy Director, Department of Nuclear Medicine, Peking Union Medical College Hospital Medical Science Research Center
Diagnosis of the main venue supervision/policy interpretation and guidance, clinical application of MRD, pathological diagnosis/marker clinical specification
Wu Nan,Vice President of Peking University Cancer Hospital
john young,Vice President of Peking University People's Hospital
True solid
The latest progress of LDT pilot interpretation and clinical landing of precise diagnosis/medical treatment
yao shukun,Former Vice President of China-Japan Friendship Hospital, Chairman of Precision Medicine Committee of Chinese Society of Bioengineering
Round table discussion: tumor precision diagnosis and treatment/drug clinical landing challenges and breakthroughs.
-
Precise diagnosis and treatment of key links to prevent disjointed the main obstacles and recommendations?
-
How to translate preclinical biomarkers into clinically actionable tests? What are the challenges?
-
Regulatory opportunities and challenges
zhong dingrong,Director, Department of Pathology, China-Japan Friendship Hospital
jiang yanfang,Director of Gene Diagnosis Center, First Hospital of Jilin University, Precision Medicine Committee of Chinese Society of Bioengineering
Secretary-General
yin xiaolu,Head of Precision Medicine, China, AstraZeneca Global R & D China Centre
Kang Xiaoyan,Chief Medical Officer, Qilu Pharmaceutical Oncology
Gong Zhaolong,Chairman and Chief Executive Officer, Siludi Pharmaceuticals
Dong ZengjunVice Chairman of Precision Medicine Professional Committee of Chinese Bioengineering Society, Partner of Kunpeng Medical Investment
NGSResearch and Development Innovation and Landing Verification of Large Panel Test Kit
Wang Xiaonan, Co-founder and Chief Technology Officer of World and Gene.
Standardized Detection of Pathology/Fusion Gene and Accurate Diagnosis and Treatment of Lung Cancer
wang zhijie,Professor, Cancer Hospital, Chinese Academy of Medical Sciences, Director of Chinese Society of Clinical Oncology (CSCO)
A New Idea of TNBC Precise Typing Diagnosis and Treatment -- Standardized Detection of HER2 Low Expression
Yuan PengProfessor Professor, Cancer Hospital, Chinese Academy of Medical Sciences
Precise Diagnosis/Analysis Cases in Hepatobiliary Tumor Targeting and Immunotherapy Instruments such as PCR/Sequencing and Related Solutions Help Accurate Tumor Detection
zhao jingmin,Director, Department of Pathology, Fifth Medical Center, Chinese PLA General Hospital
Advances in diagnostic and prognostic markers of pancreatic cancer
wang jinhua,Deputy Director, National Center for Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences
Drug Venue: CGT/Emerging Immunization Venue/Targeted Drugs
Li Ning,Vice President of Cancer Hospital, Chinese Academy of Medical Sciences, Chief Expert of Clinical Research (GCP) Platform Construction, Chinese Academy of Medical Sciences
wang tingting,Chief Operating Officer & Chief Medical Officer
Open to Sponsors
Concomitant diagnostic considerations in the development of CAR-T cell therapy transformation (tentative)
liu mingyao,Chairman, Bang Yao Bio
Tentative
he ting,Yimiao Shenzhou CEO
Translational study of CD3-bispecific antibody safety biomarkers, consideration of ADC project and exploration of clinical translation and differentiation
liao cheng,Hengrui Deputy General Manager, Head of Preclinical Development
Development of novel nano drug conjugates and strategies for translational medicine
zhang fuyao,Founder, Chairman and CEO of Shanghai Bil-Ling Biotechnology Co., Ltd.
Solutions such as bioanalysis/preclinical evaluation help in the development of innovative oncology drugs
Open to Sponsors
Bi-XDC translational medicine research and accompanying diagnostic considerations
xu qing,Senior Director, Translational Medicine, Tongyi Medicine
CAR-T drugs targeting GPRC5D and target selection considerations
he xiaowen,Hara Kai Co-Founder & Chief Medical Officer
Roundtable Discussion: How can translational medicine/biomarker research be used to improve the chances of drug development/clinical trial success?
ye bin,Hua Hui Anjian Chief Scientific Officer, Head of Translational Science
qi chuan,Senior Vice President, Global Clinical Development, Suzhou Chuangsheng Pharmaceutical Group
zhang jingyu,Head of Translational Medicine Department of Roche China
Wang Zaiqi,Chairman and CEO of Yingshi Bio
nie xiuqing,Zhejiang New Code CMO
zeng gefei,Head of Bioinformatics and Biomarkers Research, Merck R & D (China) Co., Ltd.
Drug main venue
Human Heritage Office/China Biotechnology Development Center related experts
CDE Related Experts
Bainuo Panorama
The synergy between targeting and immunotherapy: exploration of non-druggable target KRAS
Chen Lu, Director of Lilly China Medical Department, Head of Lung Cancer and Hematology Clinician Team
Application of tumor infiltrating lymphocytes (TIL) combined with artificial intelligence in clinical development of immune tumor
Chen Yunxin, Director of Precision Medicine, Bayer Oncology
Research on Transformation Progress and biomarker of Dual Immune Combination Therapy
yu yiling,BMS China R & D Biomarkers Leader
Note: The minor adjustment of the specific schedule shall be subject to the organizer.
Key words:
Latest information
Floor 3, Unit 1, Building 15, Jiajie Box Enterprise Exchange, Daxing District, Beijing
Official public number two-dimensional code
